Ibalizumab vs Semzuvolimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: CD4 receptor · full HIV pipeline
Ibalizumab · Trogarzo
Marketed by Theratechnologies and partners
NCT02707861 · Phase 3 · completed
The study was nonrandomized, open-label, and had no comparator arm, so its results cannot reliably distinguish ibalizumab’s effects from those of the individualized background regimens or other factors. Its primary effectiveness endpoint was a short-term viral-load measure, and the reported results were descriptive rather than a controlled statistical comparison.
Next expected readout: December 2028 · NCT07635992 (registry estimate)
Reported efficacy
Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF (Day 14); Efficacy: Proportion of Subjects With a Viral Load Decrease of at Least 0.5 Log 10 - Protocol Correct (Day 14): Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF (Day 14): Open-Label Ibalizumab Plus OBR 82.5% (95% CI 67.72% to 92.66%) (not_applicable)
Result source: NCT02475629
Semzuvolimab
Developed by United BioPharma
NCT04404049 · Phase 2 · status unknown
This is a small, open-label randomized study comparing two dosing schedules of add-on Semzuvolimab against standard therapy alone in people already on antiretroviral therapy. The primary measure is treatment-related side effects rather than a virologic or clinical outcome, and results are not yet available, so the evidence for Semzuvolimab's clinical benefit cannot yet be assessed. Its registered primary outcome on ClinicalTrials.gov is "treatment related TEAEs". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2026 · NCT04985890 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ibalizumab | Semzuvolimab |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | —Not reported |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Not reported |
| CD4 count, change (week 48) | —Not reported | —Not reported |
HIV-1 RNA below 50 copies/mL (week 48)
- Ibalizumab
- —Not reported
- Semzuvolimab
- —Not reported
HIV-1 RNA 50 copies/mL or more (week 48)
- Ibalizumab
- —Not reported
- Semzuvolimab
- —Not reported
CD4 count, change (week 48)
- Ibalizumab
- —Not reported
- Semzuvolimab
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Semzuvolimab: no structured comparison results are available for HIV.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ibalizumab: 4 of 4 rows · Semzuvolimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ibalizumab |
|---|---|
| Dropout rate | n/a: no completion milestoneCohort 1a NCT02707861 · Phase 3 · combination · HIV · phase 3 show 4 more resultsn/a: no completion milestoneCohort 2 NCT02707861 · Phase 3 · combination · HIV · phase 3 22.5% NCT02475629 · Phase 3 · combination · HIV · phase 3 13.6%800 mg NCT00784147 · Phase 2 · registry result, not featured evidence 16.7%2000 mg NCT00784147 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 4.9%Cohort 1a NCT02707861 · Phase 3 · combination · HIV · phase 3 show 4 more results7.9%Cohort 2 NCT02707861 · Phase 3 · combination · HIV · phase 3 2.5% NCT02475629 · Phase 3 · combination · HIV · phase 3 —800 mg NCT00784147 · Phase 2 · registry result, not featured evidence —2000 mg NCT00784147 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 39%Cohort 1a NCT02707861 · Phase 3 · combination · HIV · phase 3 show 4 more results39.5%Cohort 2 NCT02707861 · Phase 3 · combination · HIV · phase 3 22.5% NCT02475629 · Phase 3 · combination · HIV · phase 3 11.9%800 mg NCT00784147 · Phase 2 · registry result, not featured evidence 5.6%2000 mg NCT00784147 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 4 more results800 mg cough 10.2% rash 8.5% dizziness 6.8% NCT00784147 · Phase 2 · registry result, not featured evidence 2000 mg rash 16.7% nausea 13% diarrhea 11.1% NCT00784147 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ibalizumab
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 1 more result
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ibalizumab's landscape · Semzuvolimab's landscape